The reason is NEU has too many shareholders who don’t understand their investment combined with a market that doesn’t understand biotech. It’s all good here.
On the ASX biotechs can make very positive announcements and they still get marked down heavily. There are many good opportunities including NEU up for grabs.
- Forums
- ASX - By Stock
- NEU
- Ann: Plans for Phase 3 trial in Rett syndrome
Ann: Plans for Phase 3 trial in Rett syndrome, page-36
-
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B |
Open | High | Low | Value | Volume |
$14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $15.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.27 | 3638 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 15.250 |
1 | 650 | 15.200 |
1 | 40 | 15.170 |
2 | 1452 | 15.140 |
1 | 4309 | 15.130 |
Price($) | Vol. | No. |
---|---|---|
15.270 | 3638 | 4 |
15.290 | 1670 | 1 |
15.300 | 1485 | 2 |
15.330 | 1670 | 1 |
15.370 | 1670 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |